NF1 and central nervous system cancer: MEKi selumetinib and trametinib are currently employed in trials for low grade gliomas (LGG) including NF1 patients (NCT03363217, PNOC021, NCT03871257, NCT04166409, NCT04576117, NCT033263388, NCT01089101).